L189 is a DNA ligase I, III and IV inhibitor (IC50 are 5, 9 and 5 μM respectively) that blocks DNA binding.

Hydroxyurea (formerly known as NCI-c04831, NSC-32065; NCIc04831, NSC32065; Biosupressin; Carbamoyl oxime; Droxia; Hydroxycarbamide) is an approved antineoplastic drug that has been used for treating various cancers such as melanoma, sickle-cell disease and resistant chronic myelocytic leukemia.

Branaplam diHCl (LMI-070 dihydrochloride; NVS-SM1) is a potent, orally bioactive, small-molecule enhancer of SMN2 (survival of motor neuron-2) splicing that elevates full-length SMN protein and extends survival in a severe SMA mouse model.

Fluorouracil (formerly 5-FU; NSC-19893; NSC19893; 5-Fluorouracil), an analogue of uracil, is an approved anticancer medication acting as a potent DNA/RNA synthesis inhibitor.

Nedaplatin (formerly NSC-375101D; NSC 37510D; NSC-375101 D; NSC 375101-D; trade name Aqupla) is a cisplatin analog and DNA damaging agent approved as an anticancer medication.

Dactinomycin (Actinomycin IV; Actinomycin D), a compound of the actinomycine class, is a polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces.

CX-5461 (CX 5461; CX5461) is a novel, selective and orally bioavailable inhibitor of rRNA synthesis and rDNA transcription inhibitor with potential antitumor activity.

Enocitabine (NSC-239336; BHAC; Sunrabin; Arabinoside) is a cytarabine analogue, cytosine analogue and DNA chain terminator approved as an anticancer drug for the treatment of acute myeloid leukemia.

6-Mercaptopurine monohydrate (6-MP; NSC 755; 6 MP; NSC755; 6MP; NSC-755; Purinethol), the hydrated form of 6-Mercaptopurine, is an approved anticancer and immunosuppressive drug used for the treatment of ALL-acute lymphocytic leukemia, CML-chronic myeloid leukemia, Crohn’s disease, and ulcerative colitis.

Madrasin is a potent and cell penetrant splicing inhibitor that interferes with the early stages of spliceosome assembly.